Table 3.
Characteristics | Coefficient (95% Confidence Interval)b |
---|---|
Main analysisa | |
Interrupted time period at Period 4 in Year 1 | |
β0: starting level of first-time prescription rate | 471.9 (161.4 to 782.4)** |
β1: time | − 10.4 (− 51.3 to 30.5) |
β2: delayed effect of DTCI campaign (since Period 4 in Year 1) | 1128.1 (181.7 to 2074.4)* |
β3: time × delayed effect of DTCI campaign | −77.6 (− 175.0 to 19.7) |
β1 + β3: post-intervention linear trend | − 88.1 (− 170.5 to −5.60)* |
Sensitivity analysesa | |
Interrupted time period at Period 1 in Year 1 | |
β0: starting level of first-time prescription rate | 506.5 (102.0 to 911.1)* |
β1: time | −18.4 (−94.8 to 58.0) |
β2: effect of DTCI campaign (since Period 1 in Year 1) | 757.3 (− 149.4 to 1664.0) |
β3: time × DTCI campaign | −21.4 (− 129.1 to 86.3) |
β1 + β3: post-intervention linear trend | −39.8 (−99.0 to 19.4) |
Interrupted time period at Period 2 in Year 1 | |
β0: starting level of first-time prescription rate | 412.7 (−8.80 to 834.2) |
β1: time | 10.7 (−62.4 to 83.8) |
β2: effect of DTCI campaign (since Period 1 in Year 1) | 552.9 (−584.2 to 1690.0) |
β3: time × DTCI campaign | −54.4 (− 162.3 to 53.5) |
β1 + β3: post-intervention linear trend | −43.7 (− 120.3 to 32.9) |
Interrupted time period at Period 3 in Year 1 | |
β0: starting level of first-time prescription rate | 439.3 (114.0 to 764.5)* |
β1: time | −1.63 (−51.6 to 48.3) |
β2: effect of DTCI campaign (since Period 1 in Year 1) | 846.6 (− 234.8 to 1927.9) |
β3: time × DTCI campaign | −62.2 (− 158.2 to 33.7) |
β1 + β3: post-intervention linear trend | −63.9 (− 145.9 to 18.2) |
Interrupted time period at Period 5 in Year 1 | |
β0: starting level of first-time prescription rate | 393.0 (−198.7 to 984.7) |
β1: time | 12.6 (− 101.9 to 127.1) |
β2: delayed effect of DTCI campaign (since Period 4 in Year 1) | 874.4 (− 1046.5 to 2795.4) |
β3: time × delayed effect of DTCI campaign | −106.2 (− 272.2 to 59.9) |
β1 + β3: post-intervention linear trend | −93.6 (− 227.2 to 40.0) |
*p < .05 **p < .01 ***p < .001
aSample size, N1 of analyzed time periods = 30. The aggregated data samples were extracted from 1332 patients who were diagnosed with overactive bladder before May 2010 and who had not been prescribed a treatment drug during May 2010 to November 2010
bCoefficients and 95% CIs were estimated for the first-time prescription rate per 5 weeks among a standardized 100,000 patients with overactive bladder who had not used the treatment drugs previously